论文部分内容阅读
目的探讨联合用药治疗新型隐球酵母菌脑膜脑炎不良反应与合理性,以期提高临床治疗水平。方法随机选取2010年1月-2013年2月30例新型隐球酵母菌脑膜脑炎患者为研究对象,将其分为两组,各15例;对照组采用常规用药,观察组采用联合用药,分析两组患者的用药合理性及不良反应;所有数据采用SPSS13.0软件进行分析。结果两组患者治疗后在寒颤、高热比较差异无统计学意义,而在其他的不良反应的发生率比较差异有统计学意义(P<0.05),两组患者在住院费用和日均费用比较差异无统计学意义,而在住院天数、抗菌药物及激素使用比较则差异有统计学意义(P<0.05)。结论联合用药治疗新型隐球酵母菌脑膜脑炎的不良反应发生率低、用药合理。
Objective To investigate the adverse reactions and rationality of combined treatment of Cryptococcus neoformans meningoencephalitis in order to improve the clinical treatment. Methods Thirty new cases of Cryptococcus neoformans meningoencephalitis were randomly selected from January 2010 to February 2013. The patients were divided into two groups, 15 cases in each group. The control group was given routine medication, the observation group was treated with combination therapy, Analysis of two groups of patients rationality and adverse drug reactions; all data using SPSS13.0 software for analysis. Results There was no significant difference in chills and fever between the two groups after treatment, but there was significant difference in the incidence of other adverse reactions between the two groups (P <0.05). There was significant difference between the two groups in hospitalization cost and average daily cost There was no significant difference between the days of hospitalization, antimicrobial agents and hormone use (P <0.05). Conclusion The combined treatment of Cryptococcus neoformans meningitis caused a low incidence of adverse reactions, medication is reasonable.